Meeting
2018 ASCO Annual Meeting
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
Authors
Tian Zhang
Duke University Medical Center, Durham, NC
Tian Zhang , Janet S. Staats , Cliburn Chan , Michael Roger Harrison , Peter H. O'Donnell , Kristen A Batich , Tianling Chen , Cecile Krejsa , Raquel Izumi , Daniel J. George , Kent J. Weinhold
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Citation
J Clin Oncol 36, 2018 (suppl; abstr 4533)
DOI
10.1200/JCO.2018.36.15_suppl.4533
Abstract #
4533
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Association of methylation of homologous repair genes with expression of immune checkpoints in squamous cell carcinoma of head and neck, lung and cervix.
First Author: Damian Tobias Rieke
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai
Poster
2022 ASCO Annual Meeting
Comprehensive transcriptomic analysis of immune checkpoint markers in a pancancer cohort: Implications for response and resistance.
First Author: Hirotaka Miyashita
Poster
2022 ASCO Annual Meeting
Digital spatial profiling to uncover biomarkers of immunotherapy outcomes in head and neck squamous cell carcinoma.
First Author: Niki Gavrielatou